Deciphera Pharmaceuticals Inc.

13.73-0.2500-1.79%Vol 1.71M1Y Perf -61.11%
Jun 24th, 2022 16:00 DELAYED
BID12.58 ASK15.00
Open14.16 Previous Close13.98
Pre-Market- After-Market13.65
 - -  -0.08 -0.58%
Target Price
16.60 
Analyst Rating
Moderate Buy 2.40
Potential %
20.90 
Finscreener Ranking
★★★★ —    -
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★     47.11
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★ —    -
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
22.28 
Earnings Rating
Strong Buy
Market Cap909.15M 
Earnings Date
2nd Aug 2022
Alpha0.00 Standard Deviation0.22
Beta1.40 

Today's Price Range

13.3814.48

52W Range

6.5138.91

5 Year PE Ratio Range

-10.40-12.10

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
16.95%
1 Month
29.90%
3 Months
54.62%
6 Months
31.26%
1 Year
-61.11%
3 Years
-42.04%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
DCPH13.73-0.2500-1.79
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Financial StrengthValueIndustryS&P 500US Markets
3.20
3.70
0.09
0.11
-1 794.90
Leverage Ratio 1.30
ProfitabilityValueIndustryS&P 500US Markets
96.90
-284.70
-281.70
-
-
RevenueValueIndustryS&P 500US Markets
100.22M
1.57
-
-
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.84-0.804.76
Q04 2021-1.49-1.51-1.34
Q03 2021-1.29-1.37-6.20
Q02 2021-1.15-1.21-5.22
Q01 2021-1.08-1.061.85
Q04 2020-1.16-1.105.17
Q03 2020-1.32-1.1314.39
Q02 2020-1.34-1.2010.45
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.669.59Positive
9/2022 QR-0.6010.45Positive
12/2022 FY-2.6210.88Positive
12/2023 FY-1.7028.57Positive
Next Report Date2nd Aug 2022
Estimated EPS Next Report-0.66
Estimates Count7
EPS Growth Next 5 Years %-
Volume Overview
Volume1.71M
Shares Outstanding66.22K
Shares Float42.76M
Trades Count13.26K
Dollar Volume23.72M
Avg. Volume1.38M
Avg. Weekly Volume1.89M
Avg. Monthly Volume1.10M
Avg. Quarterly Volume1.15M

Deciphera Pharmaceuticals Inc. (NASDAQ: DCPH) stock closed at 13.73 per share at the end of the most recent trading day (a -1.79% change compared to the prior day closing price) with a volume of 1.71M shares and market capitalization of 909.15M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 350 people. Deciphera Pharmaceuticals Inc. CEO is Steven L. Hoerter.

The one-year performance of Deciphera Pharmaceuticals Inc. stock is -61.11%, while year-to-date (YTD) performance is 40.53%. DCPH stock has a five-year performance of %. Its 52-week range is between 6.51 and 38.91, which gives DCPH stock a 52-week price range ratio of 22.28%

Deciphera Pharmaceuticals Inc. currently has a PE ratio of -2.40, a price-to-book (PB) ratio of 2.86, a price-to-sale (PS) ratio of 7.49, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -58.23%, a ROC of -68.32% and a ROE of -73.73%. The company’s profit margin is -%, its EBITDA margin is -281.70%, and its revenue ttm is $100.22 Million , which makes it $1.57 revenue per share.

Of the last four earnings reports from Deciphera Pharmaceuticals Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.66 for the next earnings report. Deciphera Pharmaceuticals Inc.’s next earnings report date is 02nd Aug 2022.

The consensus rating of Wall Street analysts for Deciphera Pharmaceuticals Inc. is Moderate Buy (2.4), with a target price of $16.6, which is +20.90% compared to the current price. The earnings rating for Deciphera Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Deciphera Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Deciphera Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 13.18, ATR14 : 0.90, CCI20 : 200.51, Chaikin Money Flow : 0.30, MACD : 0.64, Money Flow Index : 78.56, ROC : 14.80, RSI : 64.63, STOCH (14,3) : 82.72, STOCH RSI : 0.88, UO : 67.34, Williams %R : -17.28), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Deciphera Pharmaceuticals Inc. in the last 12-months were: Daniel C. Martin (Sold 2 457 shares of value $24 465 ), Daniel Flynn (Sold 1 366 shares of value $12 362 ), Daniel L. Flynn (Sold 3 134 shares of value $31 368 ), Jama Pitman (Sold 3 590 shares of value $34 696 ), Matthew L. Sherman (Sold 5 411 shares of value $116 110 ), Thomas P. Kelly (Sold 3 136 shares of value $31 386 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (40.00 %)
4 (40.00 %)
4 (40.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
5 (50.00 %)
5 (50.00 %)
5 (50.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
1 (10.00 %)
1 (10.00 %)
1 (10.00 %)
Summary RatingModerate Buy
2.40
Moderate Buy
2.40
Moderate Buy
2.40

Deciphera Pharmaceuticals Inc.

Deciphera Pharmaceuticals Inc is a biotechnology company, which develops and manufactures kinase-inhibiting drugs for the treatment of cancers and immunological diseases. It holds a diverse pipeline of drug candidates that includes three clinical-stage and two research-stage programs. Its lead drug candidate DCC-2618 is designed to inhibit the full spectrum of mutant or amplified KIT and Pdgfra kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. In addition, it is also developing two other clinical-stage drug candidates, DCC-3014 and Rebastinib. Geographically all the operations function through the region of the United States.

CEO: Steven L. Hoerter

Telephone: +1 781 209-6400

Address: 200 Smith Street, Waltham 02451, MA, US

Number of employees: 350

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

75%25%

Bearish Bullish

67%33%

Bearish Bullish

54%46%

TipRanks News for DCPH

Sun, 08 May 2022 12:39 GMT Deciphera Pharmaceuticals (DCPH) Receives a Sell from JonesTrading

- TipRanks. All rights reserved.

Fri, 06 May 2022 01:15 GMT Analysts Conflicted on These Healthcare Names: Zymeworks (ZYME), Deciphera Pharmaceuticals (DCPH) and Arbutus Biopharma (ABUS)

- TipRanks. All rights reserved.

Thu, 28 Apr 2022 12:47 GMT Deciphera Pharmaceuticals (DCPH) Receives a Hold from JMP Securities

- TipRanks. All rights reserved.

Mon, 10 Jan 2022 23:05 GMT Deciphera Pharmaceuticals (DCPH) Gets a Hold Rating from JMP Securities

- TipRanks. All rights reserved.

News

Stocktwits